Federal Research and Clinical Center of Physical-Chemical Medicine of Federal Medical Biological Agency

Laboratory of medical genomics

Bioinformatics Immunology Genomics

Head of Laboratory

Sharova, Elena I

Publications

Citations

205

h-index

Authorization required.

We study the mechanisms of development of hereditary corneal pathologies (corneal dystrophy, keratoconus) and their genetic structure. We are developing approaches to antitumor immunotherapy, including the use of antitumor T cells. We are engaged in the genomics and population structure of microsatellite repeat expansions, including in schizophrenia. We are developing new approaches to bioinformatic data analysis. We are able to analyze the hla of macaques using nanopore readings.

Bioinformatics
Cell and tissue culture
Nanopore sequencing
In vitro tumor models: primary and conventional tumor cell cultures, tissue spheroids
Real-time PCR (qPCR)
Genome-wide and transcriptomic sequencing
Work with mammalian cell cultures, transfection
Sequencing by Sanger
Flow-through cell sorting
Work with eukaryotic cells: cultivation, transfection, infection

Elena Sharova 🥼 🤝

Head of Laboratory

Liubov Skorodumova 🥼

Researcher

Research directions

Study of the genetic structure and mechanisms of pathogenesis of hereditary corneal diseases

We study the genetics and genomics of Fuchs corneal dystrophy and keratoconus. We are engaged in identifying the mechanism of disease development in the presence of a trinucleotide repeat expansion in the TCF4 gene, and are also trying to identify new genes. We study the mechanisms of keratoconus pathogenesis and the genetic variants associated with it. To do this, we use the analysis of complete transcriptomes, exomes and genomes. We perform functional testing of new candidate variants and try single-cell transcriptomics.

Treatment of colorectal cancer with adoptive T-cell transfer

We are trying to obtain autologous antitumor T cells both on the basis of tumor-infiltrating lymphocytes and on the basis of blood mononuclear cells. To do this, we use both total and antigen-directed proliferation based on the somatic mutational profile of the tumor. In the future we want to start working with allogeneic T cells